Cerebrospinal fluid IL-10 as an early stage discriminative marker between multiple sclerosis and neuro-Behçet disease

Belghith, Mériam; Bahrini, Khadija; Kchaou, M.; Maghrebi, Olfa; Belal, Samir; Barbouche, Mohamed Ridha

doi:10.1016/j.cyto.2018.03.039

Cited by 29 publications

(12 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These cytokines have the potential to induce neutrophilic inflammation via cell adhesion molecules and other chemokines. Such neutrophilic inflammation presenting with the same cytokine profile has been also reported in NND (4,5). These findings suggest that the elevation of pro-neutrophilic cytokines is a common mechanism of neutrophilic inflammation in the CSF.…”

Section: Discussionsupporting

confidence: 81%

T-cell Lymphoma Presenting Neutrophilic Inflammation in the Cerebrospinal Fluid

et al. 2020

View full text Add to dashboard Cite

A 66-year-old woman presented with upper abdominal pain and weakness in the limbs. She had bilateral uveitis and gastric ulcers. A neurological examination revealed tetraparesis and sensory disturbance in the right arm. A cerebrospinal fluid (CSF) examination showed polymorphonuclear pleocytosis with elevated proinflammatory cytokine levels. Magnetic resonance imaging showed brain lesions and a long spinal cord lesion. She was initially diagnosed with neuro-Behçet's disease and was treated with corticosteroids, resulting in no improvement. A gastric mucosa biopsy indicated T-cell lymphoma colocalizing with neutrophils. The cytokine-mediated neutrophilic inflammation probably caused characteristic CSF and histopathological features. It is noteworthy that T-cell lymphoma may present with CSF neutrophilic inflammation.

show abstract

Section: Discussionsupporting

confidence: 81%

T-cell Lymphoma Presenting Neutrophilic Inflammation in the Cerebrospinal Fluid

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Also, the possibility of inherent reduced capacity of DC and other immune cells of multiple sclerosis patients to produce IL-10 warrants additional studies as it might be important for understanding the predisposition of humans toward the development of multiple sclerosis. Indeed, reduction in the proportion of IL-10-producing PBMC in multiple sclerosis patients (16), as well as of IL-10 mRNA expression in these cells (17, 18) were previously reported. However, multiple sclerosis patients and healthy subjects from whom blood samples were obtained were not adjusted to age, sex, and other relevant parameters that could bias our observation on the differential IL-10 response.…”

Section: Discussionmentioning

confidence: 84%

Ethyl Pyruvate Induces Tolerogenic Dendritic Cells

et al. 2019

View full text Add to dashboard Cite

Dendritic cells (DC) are professional antigen presenting cells that have a key role in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory properties and they are a promising prospective therapy for multiple sclerosis and other autoimmune diseases. Ethyl pyruvate (EP) is a redox analog of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment. We have recently shown that EP ameliorates experimental autoimmune encephalomyelitis, a multiple sclerosis murine model. Here, we expanded our study to its tolerogenic effects on DC. Phenotypic analysis has shown that DC obtained from mice or humans reduce expression of molecules required for T cell activation such as CD86, CD83, and HLA-DR under the influence of EP, while CD11c expression and viability of DC are not affected. Furthermore, EP-treated DC restrain proliferation and modulate cytokine production of allogeneic lymphocytes. These results demonstrate that EP has the ability to direct DC toward tolDC.

show abstract

“…An optimum balance between Th1 and Th2 cytokine production depends on the immune challenge. A variety of reports confirm that cytokine expression is augmented in the plasma, serum, cerebrospinal fluid, or aqueous humor of NIAU patients, or in patients at risk of NIU, with respect to healthy controls [9][10][11][56][57][58][59].…”

Section: Discussionmentioning

confidence: 99%

Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study

et al. 2021

View full text Add to dashboard Cite

The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in 72 participants distributed into: patients diagnosed with recurrent NIAU in the quiescence stage (uveitis group (UG); n = 36) and healthy controls (control group (CG); n = 36). Each group was randomly assigned to the oral supplementation of one pill/day (+) containing DHA-TG (n = 18) or no-pill condition (−) (n = 17) for three consecutive months. Data from demographics, risk factors, comorbidities, eye complications and therapy were recorded. Blood was collected and processed to determine pro-inflammatory biomarkers by bead-base multiplex assay. Statistical processing with multivariate statistical analysis was performed. The mean age was 50, 12 (10, 31) years. The distribution by gender was 45% males and 55% females. The mean number of uveitis episodes was 5 (2). Higher plasma expression of interleukin (IL)-6 was detected in the UG versus the CG (p = 5 × 10−5). Likewise, significantly higher plasma levels were seen for IL-1β, IL-2, INFγ (p = 10−4), and TNFα (p = 2 × 10−4) in the UG versus the CG. Significantly lower values of the above molecules were found in the +DHA-TG than in the -DHA-TG subgroups, after 3 months of follow-up, TNFα (p = 10−7) and IL-6 (p = 3 × 10−6) being those that most significantly changed. Signatures of circulating inflammatory mediators were obtained in the quiescent stage of recurrent NIAU patients. This 3-month follow-up strongly reinforces that a regular oral administration of DHA-TG reduces the inflammatory load and may potentially supply a prophylaxis-adjunctive mediator for patients at risk of uveitis vision loss.

show abstract

Cerebrospinal fluid IL-10 as an early stage discriminative marker between multiple sclerosis and neuro-Behçet disease

Cited by 29 publications

References 47 publications

T-cell Lymphoma Presenting Neutrophilic Inflammation in the Cerebrospinal Fluid

T-cell Lymphoma Presenting Neutrophilic Inflammation in the Cerebrospinal Fluid

Ethyl Pyruvate Induces Tolerogenic Dendritic Cells

Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study

Contact Info

Product

Resources

About